Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Panobinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 20/20 | 0.87 |
| ▸ | HDAC2 known ✓ | Q92769 | 12/20 | 0.87 |
| ▸ | HDAC3 known ✓ | O15379 | 12/20 | 0.87 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 3/20 | 0.87 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 3/20 | 0.87 |
| ▸ | HDAC4 known ✓ | P56524 | 2/20 | 0.87 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.87 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.87 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.87 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.87 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.87 |
| ▸ | NCOR2 | Q9Y618 | 10/20 | 0.87 |
| ▸ | TET3 | O43151 | 1/20 | 0.87 |
| ▸ | BRD4 | O60885 | 1/20 | 0.87 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.87 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.87 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.87 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Panobinostat SCHEMBL30235437 | 1.00 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2315067 | 1.00 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2315056 | 1.00 | HDAC1 (0.87) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2316088 | 0.99 | HDAC1 (0.86) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL2316081 | 0.99 | HDAC1 (0.86) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL183197 | 0.93 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL164801 | 0.93 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL22773814 | 0.93 | HDAC1 (1.00) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL20165843 | 0.93 | HDAC1 (0.98) | HDAC1HDAC2HDAC3NCOR2HDAC6 | |
| Panobinostat SCHEMBL436875 | 0.93 | HDAC1 (0.98) | HDAC1HDAC2HDAC3NCOR2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1786 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | claimed |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-08-26 | — | — | US | claimed |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-22 | — | — | US | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2023-05-25 | — | — | US | claimed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | claimed |
| US-20220370628-A9 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-11-24 | — | — | US | claimed |
| EP-4048260-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | Celgene Corporation (US) | 2022-08-31 | — | — | EP | claimed |
| EP-4045562-A2 | BRUSH PRODRUGS AND USES THEREOF | Massachusetts Institute of Technology (US) | 2022-08-24 | — | — | EP | claimed |
| CN-114829447-A | Brush prodrug and use thereof | 麻省理工学院 | 2022-07-29 | — | — | CN | claimed |
| WO-2022036024-A9 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3969050-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| WO-2022046850-A1 | TARGETING ABNORMAL CELL POPULATIONS FOR APOPTOSIS | KRIETZMAN, MARK H. (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2022036024-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | HDAC1 102/4885HDAC2 6/4885HDAC3 139/4885 |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | HDAC1 116/4885HDAC2 6/4885HDAC3 154/4885 |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | HDAC1 102/4885HDAC2 6/4885HDAC3 139/4885 |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | HDAC1 195/4885HDAC2 454/4885HDAC3 146/4885 |
| US-20220370628-A9 | BRUSH PRODRUGS AND USES THEREOF | ABCB11, SI, ABCB1 | HDAC1 469/4885HDAC2 1360/4885HDAC3 899/4885 |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | ABCB11, SLC10A2, CES2 | HDAC1 395/4885HDAC2 673/4885HDAC3 575/4885 |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | MEF2D, TEAD2, TEAD1 | HDAC1 186/4885HDAC2 117/4885HDAC3 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.